- Home
- NUV vs ZLAB Comparison
NUV vs ZLAB Comparison
Compare NUV & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUV | ZLAB |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NUV | ZLAB |
|---|---|---|
| Price | $9.13 | $20.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $57.22 |
| AVG Volume (30 Days) | 464.9K | ★ 887.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $441,629,000.00 |
| Revenue This Year | N/A | $40.71 |
| Revenue Next Year | N/A | $50.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $7.86 | $19.40 |
| 52 Week High | $9.08 | $44.34 |
Technical Indicators
Market Signals| Indicator | NUV | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 28.51 |
| Support Level | $9.03 | $19.40 |
| Resistance Level | $9.09 | $20.47 |
| Average True Range (ATR) | 0.05 | 0.52 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 92.86 | 22.85 |
Price Performance
Historical ComparisonAbout NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.